SIStockInvestingSI.com

NYSE · DGX · Diagnostics & Research

Quest Diagnostics Incorporated (DGX) stock analysis

$238.93+0.76%Data as of Oct 21, 2026
  • DGX gained 2.2% over the past month versus 0.0% for the S&P 500, ranking 266th of 497 S&P 500 stocks.
  • Over 12 months it returned +26.6%, 10.8 points ahead of the S&P 500, and trades 3.4% below its 52-week high.
  • In the last 30 days 2 analysts raised earnings estimates and 3 cut; forward EPS moved −0.2% (+3.1% over 90 days).
  • It sits in the Clinical laboratory services segment of the Medtech, Diagnostics & Care, where the 1-month median return is +3.0%.
  • The daily chart reads Trend transition · Trend repair (since Oct 21, 2026).
Market cap$26.4B
12-month return+26.6%
Forward P/E19.9×
Mean target vs price+5.4%

One-year price with 50- and 200-day averages

Open in Hub
179200220241JanAprJulOct
238.9350-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

DGX+2.2%
Sector median−8.7%
S&P 5000.0%
DGX+4.8%
Sector median−5.4%
S&P 500+4.7%
DGX+17.1%
Sector median−1.5%
S&P 500+8.7%
DGX+26.6%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 500266 / 497
3-month rank in its sector · Healthcare257 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Trend transition · Trend repairAwaiting confirmation

Holding since Oct 21, 2026

  • Close above EMA20 above EMA50
  • EMA50 rose over the last ten sessions
  • Intermediate and long-term directions differ
  • Neither a stable trend nor a range is confirmed
This pattern on this stock

45 occurrences in 10 years. The median move over the next 20 sessions was +2.5%, positive 67% of the time, against +1.2% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$12.04
30-day change−0.2%
90-day change+3.1%
Mean target$251.73 +5.4%
Raised (30d) 2Cut (30d) 3

15 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Ahead of peersValuation, Cash

Behind peersMomentum, Growth

PeersTMO · DHR · NTRA · A

Where it sits in the supply chain

Medtech, Diagnostics & Care · Devices, supplies & tests

Explore the full chain map in Hub
Supplied by
Laboratory & analytical tools+6.4%
TMO+5.4%1 monthDHR+6.0%1 monthA+6.4%1 monthWAT+7.5%1 monthMTD+12.6%1 monthRVTY+9.3%1 monthTECH+0.1%1 month
Its segment
Clinical laboratory services+3.0%
LH+3.9%1 monthDGX+2.2%1 month

Clinical testing turns samples into diagnostic information.

Sells into
Patients, insurers & government+11.0%
CNC+11.0%1 monthUNH+11.8%1 monthELV+7.9%1 month

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−11.6%
Volatility, 60D20.2%
From 52-week high−3.4%
From 52-week low+39.0%
Trailing P/E25.4×
Forward P/E19.9×
LHLabcorp Holdings Inc.TMOThermo Fisher ScientificDHRDanaherAAgilent Technologies, Inc.WATWaters CorporationMTDMettler-Toledo International, IRVTYRevvity, Inc.TECHBio-Techne Corp

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗